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Background: Gene silencing of O6-methylguanine–DNA methyltransferase (MGMT) by promoter methylation
improves the outcome of glioblastoma patients after combined therapy of alkylating chemotherapeutic agents
and radiation. The purpose of this study was to assess the frequency of MGMT promoter methylation in soft
tissue sarcoma to identify patients eligible for alkylating agent chemotherapy such as temozolomide.
Findings: Paraffin tumor blocks of 75 patients with representative STS subtypes were evaluated. The methylation
status of the MGMT promoter was assessed by methylation-specific polymerase-chain-reaction analysis (PCR).
Furthermore, immunohistochemistry was applied to verify expression of MGMT. MGMT gene silencing was
assumed if MGMT promoter methylation was present and the fraction of tumor cells expressing MGMT was 20%
or less. Methylation specific PCR detected methylated MGMT promoter in 10/75 cases. Immunohistochemical
staining of nuclear MGMT was negative in 15/75 cases. 6/75 tumor samples showed MGMT promoter methylation
and negative immunohistochemical nuclear staining of MGMT. In none of the tested STS subtypes we found a
fraction of tumors with MGMT silencing exceeding 22%.
Conclusion: MGMT gene silencing is a rare event in soft tissue sarcoma and cannot be recommended as a
selection criterion for the therapy of STS patients with alkylating agents such as temozolomide.
Keywords: Soft tissue sarcoma, O6-methylguanine–DNA methyltransferase, Promoter methylation, Temozolomide,
Epigenetic gene silencing, Radiation therapyFindings
Hypothesis
Soft tissue sarcoma (STS) form a heterogeneous group of
malignant tumors arising in the mesenchymal tissues. A
considerable fraction of patients presents with locally
advanced disease and requires multimodal therapy includ-
ing chemotherapy or chemoradiation [1]. Doxorubicin and
ifosfamid are generally recommended for first line systemic
treatment in unresectable and/or metastatic STS. A variety
of other chemotherapeutic substances have been tested in
phase II trials but were never compared to standard treat-
ment in phase III trials although some of them may be
regarded as active drugs in STS [2]. Temozolomide is an* Correspondence: jens.jakob@umm.de
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reproduction in any medium, provided the ororal prodrug of 3-methyl-(triazen-1yl)imidazole-4-carboxi-
mide, the active metabolite of the alkylating agent DTIC
[3]. In combination with radiation therapy, temozolomide
has substantially improved overall survival in glioblastoma
patients and has altered the standard of care in glioblast-
oma treatment [4]. The activity of temozolomide in glio-
blastoma patients relies on gene silencing of the MGMT
(O6-methylguanine–DNA methyltransferase) DNA repair
gene, though [5]. In STS, temozolomide the activity of
temozolomide seems to be schedule dependent [6,7]. The
combination of temozolomide with irradiation which would
be suitable for neoadjuvant treatment of locally advanced
STS seems to be well tolerable and reveals promising
response rates [8]. Further phase II and/or III trials are ne-
cessary to evaluate the efficacy of temozolomide combined
with irradiation. The design of these trials must take into
account MGMTgene silencing for its impact on the activity
of temozolomide. The purpose of the present study wastd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in soft tissue sarcoma in order to identify patients
and/or histological subtypes that may be suitable for
treatment with alkylating agents and irradiation in the
setting of a phase II trial.Methods
Paraffin blocks of tumor biopsie or resections of 75
patients with representative histological sarcoma subtypes
were obtained from the local tumor tissue bank (Table 1).
These tumor blocks were analysed by methylation specific
polymerase chain reaction (PCR) and immunohistoche-
mistry to detect MGMT gene silencing. Ethical approval
was obtained from the Medical Ethics Committee II,
University of Heidelberg (Reference number 2006-154N-
MA). Written informed consent was obtained from the
patient for publication of this report.
For methylation specific PCR, genomic DNA was isolated
from paraffin sections of the selected tissue blocks and
bisulfite converted with a commercial kit (EpiTect Plus
FFPE Bisulfite Kit; Qiagen; Hilden, Germany) according to
the manufacturer’s instructions. The bisulfite treated DNAs
were amplified by a two-step PCR approach to improve the

























other 9round of amplification the primer sequences were
5’-GGATATGTTGGGATAGTT-3’ (MGMT-F) and 5’-
CCAAAAACCCCAAACCC-3’ (MGMT-R). PCR con-
ditions included an annealing temperature of 52°C and
40 cycles of amplification. For nested PCRs with specific
primer sets for un-methylated and methylated samples 1μl
of the first round amplification product was used at an
annealing temperature of 60° with 35 amplification cycles.
Primer sequences of MGMT for the unmethylated reaction
were 5’-TTT GTG TTT TGA TGT TTG TAG GTT TTT
GT-3’ (MGMT-UUP) and 5’-AAC TCC ACA CTC TTC
CAA AAA CAA AAC A-3’ (MGMT-ULP). The sequences
of MGMT for the methylated reaction were 5’-TTT CGA
CGT TCG TAG GTT TTC GC-3’ (MGMT-MUP) and 5’-
GCA CTC TTC CGA AAA CGA AAC G-3’ (MGMT-
MLP). PCR products were separated and visualized on a
QIAxcel electrophoresis system (Qiagen, Hilden, Germany).
As a control we selected several cases of glioblastoma with
MGMT promoter methylation and negative control sam-
ples without DNA and included both for each set of PCR.
Immunohistochemical analysis of formalin-fixed,
paraffin-embedded sections of the selected tumor
samples was performed according to standard proto-
cols. The primary antibody used was MGMT Monoclonal
Antibody MT 23.2 (Pierce Antibodies, Il USA) after heat
antigen retrieval in pH 9 buffer (Dako, Glostrup, Denmark).
Only nuclear staining was considered positive. MGMT ex-
pression was considered lost when there were 20% or less
stained tumor cell nuclei.
MGMT gene silencing was assumed if methylation
specific PCR detected MGMT promoter methylation
AND immunohistochemistry demonstrated MGMT ex-
pression in less or equal than 20% of tumor cells. Results
of these analyses are presented descriptively. Median
and range are given if appropriate.
Results
Methylation specific PCR detected unmethylated MGMT
promoter in 65/75 cases. In 10/75 tumor samples we found
MGMT promoter methylation. Yet, in each of these cases
also unmethylated MGMT promoter was detected. An
example of the methylation specific PCR is given in
Figure 1.
Immunohistochemical staining showed inhomogen-
eous expression of MGMT in most patients. Immuno-
histochemistry was regarded negative in 15/75 cases. An
example of negative and positive staining for MGMT is
depicted in Figure 2.
In 6/75 tumor samples we detected both MGMT
promoter methylation and negative staining of MGMT.
In none of the tested STS subtypes we found a fraction
of tumors with MGMT silencing (MGMT promoter
methylation and negative immunohistochemistry for
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Figure 1 Example of methylation specific PCR for unmethylated and methylated MGMT Promoter. U: unmethylated, M. methylated.
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types, without preference for a specific entity.
Conclusions
The purpose of the present study was to determine the
frequency of MGMT gene silencing in soft tissue sar-
coma in order to identify STS patients and/or histo-
logical subtypes that may be suitable for treatment with
alkylating agents and irradiation in a phase II clinical
trial with MGMT promoter methylation being a criter-
ion for selection or stratification. The rationale behind
the study was that glioblastoma patients with MGMT
gene silencing benefit from chemotherapy with the alky-
lating agent temozolomide in combination with ra-
diation therapy [4].
We selected a set of paraffin blocks of representative
STS subtypes and performed MGMT promoter methyla-
tion analysis and immunohistochemistry which demon-
strated MGMT gene silencing in only 6/75 of the
evaluated tumors. Even in those tumors where MGMT
promoter methylation was present, we were able to de-
tect tumor cells with non-methylized MGMT promoter.
This phenomenon may be explained by intratumoral
heterogeneity or by the detection of non-methylizedFigure 2 Example of immunohistochemistry for MGMT in two cases o
2: negative staining.MGMT promoter in tumor infiltrating lymphocytes,
blood vessels or normal tissue as described before [5,10].
Furthermore the various qualitative and quantitative
methods for the analysis of MGMT promoter methyla-
tion may reveal divergent results even if the sequences
tested are overlapping or identical [11,12]. That was the
reason to perform additional immunohistochemistry
of MGMT expression in all cases of this cohort that
confirmed expression of MGMT in most tumors.
Two other groups published data on MGMT gene
silencing of STS in Asian populations. Kim et al. exa-
mined 62 cases of liposarcoma, leiomyosarcoma, malig-
nant peripheral nerve sheath tumor (MPNST), malignant
fibrous histiocytoma (MFH) and synovial sarcoma and
reported MGMT promoter methylation in 21/62 cases
[13]. Kawaguchi et al. studied the methylation of the
MGMT promoter in MFH, MPNST and leiomyosarcoma
and found MGMT promoter methylation in 10/65 tumor
samples [14]. The rate of tumor samples examined after
pretreatment was not reported. Despite differences in
methods, patient populations and tumor subtypes in the
present and the previously published studies, it is ob-
vious that MGMT gene silencing is a rare event in soft
tissue sarcoma. Furthermore no histological subtype canf STS Non Otherwise Specified (NOS). 1: positive staining,
Table 2 Fraction of tumors with MGMT gene silencing











Liposarcoma 2/18 3/18 2/18
MFH/NOS 1/15 3/15 1/15
MPNST 3/10 3/10 1/10
Leiomyosarcoma 1/14 2/14 1/14
Synovial Sarcoma 1/7 0/7 0/7
Myxofibrosarcoma 2/11 4/11 1/11
Jakob et al. Radiation Oncology 2012, 7:180 Page 4 of 4
http://www.ro-journal.com/content/7/1/180be identified that would exhibit MGMT promoter
methylation in a relevant fraction of tumors in more
than one of the studies.
A selection criterion for a personalized therapy in soft
tissue sarcoma should be easy and reliable to assess, dis-
criminate between tumors that are targeted well and
positive in a relevant number of patients [15]. Although
MGMT gene silencing may increase the effect of alkylat-
ing agents given in combination with irradiation, we be-
lieve that the frequency of MGMT gene silencing is too
low to use it as a selection or stratification criterion in a
phase II trial of concomitant irradiation and alkylating
agent therapy.
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